370 related articles for article (PubMed ID: 19667187)
1. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice.
Tong Y; Pisani A; Martella G; Karouani M; Yamaguchi H; Pothos EN; Shen J
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14622-7. PubMed ID: 19667187
[TBL] [Abstract][Full Text] [Related]
2. Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.
Tsika E; Kannan M; Foo CS; Dikeman D; Glauser L; Gellhaar S; Galter D; Knott GW; Dawson TM; Dawson VL; Moore DJ
Neurobiol Dis; 2014 Nov; 71():345-58. PubMed ID: 25174890
[TBL] [Abstract][Full Text] [Related]
3. Genetic analysis of Parkinson's disease-linked leucine-rich repeat kinase 2.
Tong Y; Shen J
Biochem Soc Trans; 2012 Oct; 40(5):1042-6. PubMed ID: 22988862
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
Tozzi A; Durante V; Bastioli G; Mazzocchetti P; Novello S; Mechelli A; Morari M; Costa C; Mancini A; Di Filippo M; Calabresi P
Neurobiol Dis; 2018 Oct; 118():1-8. PubMed ID: 29908325
[TBL] [Abstract][Full Text] [Related]
5. (R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model.
Weng YH; Chen CY; Lin KJ; Chen YL; Yeh TH; Hsiao IT; Chen IJ; Lu CS; Wang HL
Exp Neurol; 2016 Jan; 275 Pt 1():104-15. PubMed ID: 26363496
[TBL] [Abstract][Full Text] [Related]
6. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
[TBL] [Abstract][Full Text] [Related]
7. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P
Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188
[TBL] [Abstract][Full Text] [Related]
8. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
[TBL] [Abstract][Full Text] [Related]
9. Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations.
Chen C; Soto G; Dumrongprechachan V; Bannon N; Kang S; Kozorovitskiy Y; Parisiadou L
Elife; 2020 Oct; 9():. PubMed ID: 33006315
[TBL] [Abstract][Full Text] [Related]
10. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.
Volta M; Cataldi S; Beccano-Kelly D; Munsie L; Tatarnikov I; Chou P; Bergeron S; Mitchell E; Lim R; Khinda J; Lloret A; Bennett CF; Paradiso C; Morari M; Farrer MJ; Milnerwood AJ
Parkinsonism Relat Disord; 2015 Oct; 21(10):1156-63. PubMed ID: 26282470
[TBL] [Abstract][Full Text] [Related]
11. R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations.
Xenias HS; Chen C; Kang S; Cherian S; Situ X; Shanmugasundaram B; Liu G; Scesa G; Savio Chan C; Parisiadou L
Commun Biol; 2022 Nov; 5(1):1211. PubMed ID: 36357506
[TBL] [Abstract][Full Text] [Related]
12. Parkinson's disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging.
Chen X; Xie C; Tian W; Sun L; Zheng W; Hawes S; Chang L; Kung J; Ding J; Chen S; Le W; Cai H
Mol Neurodegener; 2020 Feb; 15(1):12. PubMed ID: 32075681
[TBL] [Abstract][Full Text] [Related]
13. LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease.
Yao C; El Khoury R; Wang W; Byrd TA; Pehek EA; Thacker C; Zhu X; Smith MA; Wilson-Delfosse AL; Chen SG
Neurobiol Dis; 2010 Oct; 40(1):73-81. PubMed ID: 20382224
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.
Ramonet D; Daher JP; Lin BM; Stafa K; Kim J; Banerjee R; Westerlund M; Pletnikova O; Glauser L; Yang L; Liu Y; Swing DA; Beal MF; Troncoso JC; McCaffery JM; Jenkins NA; Copeland NG; Galter D; Thomas B; Lee MK; Dawson TM; Dawson VL; Moore DJ
PLoS One; 2011 Apr; 6(4):e18568. PubMed ID: 21494637
[TBL] [Abstract][Full Text] [Related]
15. LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory.
Beccano-Kelly DA; Volta M; Munsie LN; Paschall SA; Tatarnikov I; Co K; Chou P; Cao LP; Bergeron S; Mitchell E; Han H; Melrose HL; Tapia L; Raymond LA; Farrer MJ; Milnerwood AJ
Hum Mol Genet; 2015 Mar; 24(5):1336-49. PubMed ID: 25343991
[TBL] [Abstract][Full Text] [Related]
16. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.
Zhou H; Huang C; Tong J; Hong WC; Liu YJ; Xia XG
Int J Biol Sci; 2011; 7(6):753-61. PubMed ID: 21698001
[TBL] [Abstract][Full Text] [Related]
17. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
[TBL] [Abstract][Full Text] [Related]
18. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.
Yue M; Hinkle KM; Davies P; Trushina E; Fiesel FC; Christenson TA; Schroeder AS; Zhang L; Bowles E; Behrouz B; Lincoln SJ; Beevers JE; Milnerwood AJ; Kurti A; McLean PJ; Fryer JD; Springer W; Dickson DW; Farrer MJ; Melrose HL
Neurobiol Dis; 2015 Jun; 78():172-95. PubMed ID: 25836420
[TBL] [Abstract][Full Text] [Related]
19. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
[TBL] [Abstract][Full Text] [Related]
20. Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice.
Xiong Y; Neifert S; Karuppagounder SS; Liu Q; Stankowski JN; Lee BD; Ko HS; Lee Y; Grima JC; Mao X; Jiang H; Kang SU; Swing DA; Iacovitti L; Tessarollo L; Dawson TM; Dawson VL
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1635-1640. PubMed ID: 29386392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
